News | Advanced Visualization | September 07, 2017

Median Technologies to Lead Roundtable on Applications of iBiopsy for Nonalcoholic Steatohepatitis

Panelists will include four key opinion leaders in the fields of hepatology, liver imaging, biomarker and non-invasive test development and clinical trial design

Median Technologies to Lead Roundtable on Applications of iBiopsy for Nonalcoholic Steatohepatitis

September 7, 2017 — Median Technologies announced that it will lead a scientific and medical roundtable on Sept. 7 in Sophia-Antipolis, France, to discuss the application of its next-generation imaging platform iBiopsy for nonalcoholic steatohepatitis (NASH). The roundtable panel will include four key opinion leaders:

  • Richard Jones, M.D., MRCP, vice president, general medicine, Princeton, N.J. Jones is a GMC-registered physician from the United Kingdom specializing in internal medicine, clinical pharmacology and cardiology. He qualified from the Universities of Cambridge and Oxford and has spent more than 15 years in academic medicine in the UK. Jones has over 70 publications on various aspects of drug development. He worked in early- and late-phase drug development holding senior positions in several major pharmaceutical companies. He has experience in developing novel biomarkers and non-invasive tests and their application to clinical trial methodologies;
  • Rohit Loomba, M.D., MHSc, University of California, San Diego (UCSD). Loomba is a professor of medicine (with tenure), director of hepatology, and vice chief, Division of Gastroenterology at UCSD. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and in non-invasive assessment of steatosis and fibrosis using advanced imaging modalities;
  • Michael Middleton, M.D., Ph.D., UCSD. Together with others at UCSD, Middleton has developed and improved breath-hold quantitative magnetic resonance (MR) magnitude imaging and spectroscopic methods to assess liver fat, and has developed methods to assess the adequacy of MRI proton density fat fraction (PDFF) and magnetic resonance elastography (MRE) liver stiffness assessment measurements. Middleton and his group use MRI to assess liver fat content in clinical trials for the NASH Clinical Research Network, and he currently serves on the Steering and Radiology Committees of the NASH CRN; and
  • Massimo Pinzani is professor of medicine at University College London (UCL), London, United Kingdom. He is a clinical and translational hepatologist, is the Sheila Sherlock Chair of Hepatology and director of the UCL Institute for Liver and Digestive Health, Division of Medicine.  Pinzani is one of the pioneers in research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches.

The roundtable will aim at providing scientific and medical insights and recommendations to support the development and strategic positioning of Median's  iBiopsy for NASH.

"Median Technologies is developing imaging biomarkers for the diagnosis and assessment of treatment response of NASH patients during clinical trials that will lead to the development of a companion diagnostic imaging test once a drug has been approved by the FDA [U.S. Food and Drug Administration]. Our plan is to have the imaging biomarker validated during the clinical trial becoming the basis for the companion diagnostic. We have been evaluating various imaging protocols and modalities including CT [computed tomography] contrast imaging and MR elastography combined with novel deep learning methodologies," said Fredrik Brag, CEO of Median Technologies. 

iBiopsy (Imaging Biomarker Phenotyping System) is a platform that combines non-invasive image biomarkers with phenomics. This combination of science and technology can provide insights into development of novel therapies and individualized treatment strategies. iBiopsy can measure disease and treatment response without an invasive and costly biopsy.

For more information:

Related Content

Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
3-D Imaging and Computer Modeling Capture Breast Duct Development

An image of a developing mammary duct. Image courtesy of Andrew Ewald.

News | Breast Imaging | June 28, 2018
A team of biologists has joined up with civil engineers to create what is believed to be the first 3-D computer model...
3D Systems Announces On Demand Anatomical Modeling Service
Technology | Medical 3-D Printing | June 18, 2018
3D Systems announced availability of its new On Demand Anatomical Modeling Service. This new service provides a wide...
Technology | Orthopedic Imaging | June 13, 2018
EOS imaging announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its hipEOS...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.


News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Researchers Use Radiomics to Overcome False Positives in Lung Cancer CT Screening
News | Advanced Visualization | May 29, 2018
A team of researchers including investigators from Mayo Clinic has identified a technology to address the problem of...
Intelerad Launches AI Initiative for Imaging Workflow Intelligence and Analytics
News | Artificial Intelligence | May 29, 2018
Intelerad Medical Systems announced the launch of its artificial intelligence (AI) initiative along with the expansion...
EnvoyAI, TeraRecon and Insignia Bringing Artificial Intelligence to U.K. Customers
Technology | Advanced Visualization | May 11, 2018
EnvoyAI announced a new integration with Insignia Medical Systems’ InSight PACS (picture archiving and communication...